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Abstract
Background: Complementary and alternative medicine (CAM) use is often not disclosed by patients, and can
be unfamiliar to health care professionals. This may lead to underuse of beneficial CAM therapies, and overuse
of other CAM therapies with little proven benefit or known contraindications. No prior research has thoroughly
evaluated the credibility of knowledge-based resources. The purpose of this research was to assess the quantity and
quality of CAM guidelines.
Methods: A systematic review was conducted to identify CAM guidelines. MEDLINE, EMBASE and CINAHL
were searched in January 2016 from 2003 to 2015. The National Guideline Clearinghouse, National Center for
Complementary and Integrative Health web site, and two CAM journals were also searched. Eligible guidelines
published in English language by non-profit agencies on herbal medicine, acupuncture, or spinal manipulation
for adults with any condition were assessed with the Appraisal of Guidelines, Research and Evaluation II
(AGREE II) instrument.
Results: From 3,126 unique search results, 17 guidelines (two herbal medicine, three acupuncture, four spinal
manipulation, eight mixed CAM therapies) published in 2003 or later and relevant to several clinical conditions
were eligible. Scaled domain percentages from highest to lowest were clarity of presentation (85.3 %), scope
and purpose (83.3 %), rigour of development (61.2 %), editorial independence (60.1 %), stakeholder involvement
(52.0 %) and applicability (20.7 %). Quality varied within and across guidelines. None of the 17 guidelines
were recommended by both appraisers; 14 were recommended as Yes or Yes with modifications.
Conclusions: Guidelines that scored well could be used by patients and health care professionals as the basis
for discussion about the use of these CAM therapies. In future updates, guidelines that achieved variable or
lower scores could be improved according to specifications in the AGREE II instrument, and with insight from
a large number of resources that are available to support guideline development and implementation. Future
research should identify CAM therapies other than those reviewed here for which guidelines are available.
Research is also needed on the safety and effectiveness of CAM therapies.
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Background
It is currently estimated that more than 70 % of North
Americans have tried at least one form of complemen-
tary and alternative medicine (CAM), [1–3] collectively
spending billions of dollars annually on these therapies
[4, 5]. CAM has been defined as “a group of diverse
medical and health care interventions, practices, pro-
ducts or disciplines that are not generally considered
part of conventional medicine” [6]. The National Center
for Complementary and Integrative Health (NCCIH)
further defines a non-mainstream practice used together
with conventional medicine as “complementary”, a non-
mainstream practice used in place of conventional medi-
cine as “alternative”, and the coordinated delivery or
use of conventional and complementary approaches as
“integrative” [6]. This study henceforth refers to therapies
that fall into all of these categories as CAM.
The past several decades have seen a sharp increase in
research on CAM given the strong patient-driven market
[7]. Examples of well-studied CAM therapies that show
potential benefit include chiropractic spinal manipulation
for low back pain and headaches [8–12], and acupuncture
for different types of pain [13–18]. Recognizing such
benefits, academic institutions are increasingly incorpora-
ting CAM into medical education, research and practice
[11]. However, a variety of factors appear to influence
whether and how CAM is used. Patients may not discuss
their use of CAM with health care professionals out of
fear of being judged or not seeing this as important
to disclose, potentially leading to contraindications with
other treatment [19–22]. Many health care professionals
were not exposed to CAM in their medical training [23],
are unfamiliar with CAM therapies, and find it challenging
to discuss use or disuse of CAM with their patients [24,
25]. This is exacerbated by the fact that CAM is com-
prised of many different and unrelated types of therapies
and schools of thought about their use [26]; and the reli-
ability of evidence about safety and effectiveness varies
between CAM therapies [27–29]. Given all of these fac-
tors, concerns have been raised about legal and ethical is-
sues pertaining to the recommendations that health care
professionals offer their patients about using or not
using CAM therapies [24, 30]. Hence, patients and
health care professionals may benefit from credible,
knowledge-based resources upon which to base discus-
sions and decisions about use of CAM.
Health care professionals often rely on evidence-
informed clinical practice guidelines to understand
whether use of a given therapy is recommended, and
as a basis for informed and shared decision-making
with patients about associated risks and benefits [31].
Research on a variety of clinical topics has identified that
overuse, underuse or misuse of therapies may be asso-
ciated with guidelines that are of poor quality [32], and
the quality of guidelines has been proven to vary consi-
derably [33]. Few studies have examined CAM guidelines.
Content analysis of 10 guidelines on cardiovascular dis-
ease and type II diabetes revealed that CAM-relevant
information was brief, in some cases unclear, inconclusive
and lacking in direction for health care professionals [34].
Analysis of 65 National Institute for Health and Clinical
Excellence guidelines available in 2009 found that, among
17 guidelines that mentioned CAM, it was not clinically
relevant to most; in 14 of 48 guidelines that did not
mention CAM, available evidence on the safety and
effectiveness of relevant CAM therapies had not been
included [35]. Therefore, no research has thoroughly
evaluated the credibility of CAM guidelines. An under-
standing of the nature of CAM guidelines available to
support informed and shared decision-making among
patients and providers would help to identify whether
such resources are absent and thus needed, or how they
could be improved, thereby guiding future guideline
development and associated research. The purpose of this




A systematic review was conducted to identify CAM
guidelines using standard methods [36] and Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) criteria [37]. A protocol was not registered.
Eligible guidelines were assessed with the widely used
and validated Appraisal of Guidelines, Research and
Evaluation II (AGREE II) instrument [38]. AGREE II
is a tool that assesses the methodological rigour and
transparency in which a guideline is developed, and is
the international “gold standard” for the assessment
of guidelines. Detailed information is available on the
AGREE web site [www.agreetrust.org]. It consists of
23 items grouped in six domains: scope and purpose,
stakeholder involvement, rigor of development, clarity
and presentation, applicability, and editorial independence.
Eligibility criteria
Eligibility criteria for CAM guidelines were based on the
Population, Intervention, Comparison and Outcomes
framework. Eligible populations were adults aged 19 years
and older with any diseases or conditions. With respect
to interventions, guidelines were more likely to have
been published on CAM interventions for which evidence
has accumulated. We referred to a bibliometric and
content analysis of CAM trials in the Cochrane Library by
Wieland et al. [39] which found that the CAM therapies
most commonly evaluated in trials included herbal
supplements (non-vitamin, non-mineral dietary supple-
ments or Chinese herbal medicine), acupuncture, and
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chiropractic or osteopathic manipulation [39]. For this
study, guidelines were eligible if they specifically focused
on any of these CAM therapies (category 1 – CAM-
specific), or were general CAM guidelines that included
at least one recommendation (for or against) at least
of these CAM therapies (category 2 – CAM-general).
We excluded general guidelines, which includes many
hundreds and perhaps thousands, as it would have been
challenging to search for and screen them for potential
mention of CAM. Comparisons pertained to the assessed
quality of CAM guidelines. Outcomes were AGREE II
scores which reflect guideline content and format. The
following conditions were also applied to define eligible
guidelines: developed by non-profit organizations inclu-
ding academic institutions, government agencies, disease-
specific foundations, or professional associations or
societies; published in 2003 or later, which corresponds
to the publication of AGREE II which provides deve-
lopers with criteria for developing high-quality guide-
lines; English language; and either publicly available
or could be ordered through our library system. Publica-
tions in the form of consensus statements, protocols,
abstracts, conference proceedings, letters or editorials;
based on primary studies that evaluated CAM therapies;
or focused on CAM curriculum, education, training,
research, professional certification or performance were
not eligible.
Searching and screening
MEDLINE, EMBASE and CINAHL were searched on
January 28, 2016 from 2003 to 2015 inclusive. The
search strategy (Additional file 1) included Medical
Subject Headings and keywords that reflect terms
commonly used in the literature to refer to CAM [7].
We also searched the National Guideline Clearinghouse, a
publicly available repository of guidelines [http://www.gui
deline.gov/] using keyword searches restricted based on
the eligibility criteria including “acupressure”, “acupunc-
ture”, “Chinese medicine”, “chiropractic”, “chiropractor”,
“herbal medicine”, “herbal supplement”, “herbal therapy”,
“osteopath”, “phytotherapy”, “plant extract” and “spinal
manipulation”. Next, we searched the NCCIH web site
which contained a single list of CAM guidelines [https://
nccih.nih.gov/health/providers/clinicalpractice.htm]; and
the tables of contents of two CAM journals with the
highest impact factors: BMC Complementary and Alter-
native Medicine [https://bmccomplementalternmed.bio
medcentral.com/] and the Journal of Complementary and
Alternative Medicine [http://www.liebertpub.com/over
view/journal-of-alternative-and-complementary-medicine-
the/26/] from January 2011 and December 2015. All three
authors independently screened the titles and abstracts
recovered from MEDLINE to standardize screening by
discussing and resolving selection differences. Following
this, JYN and LL screened titles and abstracts from all
other sources. JYN and ARG screened full-text items to
confirm eligibility.
Data extraction and analysis
The following data were extracted from each guideline
and summarized: date of publication, country of first
author; type of organization that published the guideline
(academic institutions, government agencies, disease-spe-
cific foundations, or professional associations or soci-
eties); topic category 1 (CAM-specific) or category 2
(CAM-general); and guideline topic including type of
CAM therapy and disease or condition. Most data
were available in the guideline; to assess applicability,
the web site of each developer was browsed and searched
for any associated knowledge-based resources in support
of implementation.
Guideline quality assessment
The extraction and analysis of data from eligible guide-
lines followed standardized methods for applying the
AGREE II instrument [38]. To do this we used the
instructional manual provided by AGREE for this
purpose. This is a 60-page document that first describes
the AGREE instrument, provides instructions on how
to apply the instrument then, for each domain, provides
detailed guidance on where to look in the guideline for
relevant content to judge that domain and how to rate
each item in that domain. First a pilot test of the AGREE
II instrument was conducted with two guidelines during
which all three authors independently assessed both
guidelines with the AGREE II instrument. Discrepancies
were discussed and resolved. JYN and LL then indepen-
dently assessed all eligible guidelines for 23 items across
six domains using a seven-point Likert scale from strongly
disagree (1) to strongly agree (7) that the item is met;
rated the overall quality of each guideline (1 to 7); and
used that information to recommend for or against
use of each guideline. ARG resolved differences. Average
appraisal scores were calculated by taking the average
rating for all 23 items of a single appraiser of a single
guideline, followed by taking the average of this value
for both appraisers. Average overall assessments were
calculated as the average of both appraisers’ “overall
guideline assessment” scores for each guideline. Scaled
domain percentages were generated for inter-domain
comparison, and were calculated by adding both appraisers’
ratings of items within each domain, and scaling by
maximum and minimum possible domain scores, before
converting this into a percentage. Average appraisal scores,
average overall assessments and scaled domain percentages
for each guideline was tabulated for comparison.
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Results
Search results (Fig. 1)
Searches retrieved 3,350 items, 3,126 were unique, and
3,095 titles and abstracts were eliminated, leaving 31
full-text guidelines that were considered. Of those, 14
were not eligible, primarily because they were not
focused on CAM (7), they could not be retrieved (3), or
did not meet other eligibility criteria (4), leaving 17
guidelines eligible for review.
Guideline characteristics (Table 1)
Eligible guidelines were published in 2003 or later in
Canada, the United States, United Kingdom, China, and
Australia [40–56]. The guidelines were funded and/or
developed by professional associations or societies (13),
academic (3), and an international agency (1). Nine
guidelines were CAM-specific (2 herbal medicine, three
acupuncture, four spinal manipulation) and 8 were
CAM-general. Clinical topics included anorexia nervosa,
breast cancer, cancer (general) diabetes, headache, herpes
zoster, low back pain, lung cancer, major depressive
disorder, migraine, multiple sclerosis, neck pain, and
Parkinson’s disease.
Average appraisal scores, average overall assessments
and recommendations regarding use of guidelines
Average appraisal scores, average overall assessments,
and recommendation regarding use for each guideline
are shown in Additional file 2. The average appraisal
scores for each of the 17 guidelines ranged from 3.3 to
5.5 on the seven-point Likert scale (where seven equals
strongly agree that the item is met); 14 guidelines
achieved or exceeded an average appraisal score of 4.0,
and seven guidelines achieved or exceeded an average
appraisal score of 5.0. Average overall assessments for
the 17 guidelines ranged between 3.0 (lowest) and 5.5
(highest), including 14 guidelines equalling or exceeding
a score of 4.0, and 7 guidelines equalling or exceeding a
score of 5.0.
Overall recommendations (Table 2)
None of the 17 guidelines were recommended by both
appraisers. Appraisers agreed in their overall recommen-
dation for 13 of 17 guidelines including 2 No [52, 55],
and 11 Yes with modifications [40–43, 47–49, 51, 53, 54,
56]. Of the remaining four guidelines, three were rated
by the two appraisers as No and Yes with modifications
[44, 45, 50], while 1 guideline was rated at Yes and
Yes with modifications [46].
Scaled domain percentage quality assessment (Table 3)
With regards to scaled domain percentages, scope
and purpose scores were 52.8 to 100.0 %, stakeholder
involvement scores were 11.1 to 86.1 %, rigor-of-
development scores were 14.6 to 92.7 %, clarity-of-
presentation scores ranged from 69.4 to 97.2 %,
applicability scores were 0.00 to 60.42 %, and editorial
independence scores ranged from 0.0 to 95.8 %.
Scope and purpose
The overall objectives and health questions were gene-
rally well-defined in all but one guideline [45]. Authors
provided the goal of the guideline, the types of CAM
they sought to assess, and the disease or condition that
Fig. 1 PRISMA diagram
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was the target of CAM therapy or therapies. The popu-
lation to whom the guideline was meant to apply was
sometimes less detailed. For example, two guidelines
referred to the intended population as “patients” [46, 48].
Stakeholder involvement
Most guidelines thoroughly in detailed the characteris-
tics of the members of the guideline development group,
typically including degrees held by, and institutional
affiliation of each member, in addition to some of the
following: subject discipline, geographical location, and
description of member’s role in the group [41–44, 46–
49, 53–56]. Some guidelines detailed the views and
preferences of the target population [44, 46, 53, 56] while
most did not [40–43, 45, 47–52, 54, 55]. Target users of
the guideline were typically inconsistently defined. Some
guidelines offered clear descriptions, for example, type of
practitioner, specialty [40, 46, 49, 50, 52, 53, 56], while
other guidelines offered few details about target users
[43, 45, 47, 50, 54, 55].
Rigor of development
Systematic methods were almost always used to search
for evidence and the criteria for selecting the evidence
were almost always clearly described [40–44, 46–51, 53,
54, 56], with the exception of a few guidelines [45, 52, 55].
The strengths and limitations of the body of evidence
were clearly described in all guidelines except for one [45].
The methods for formulating the recommendations
varied; while some guidelines provided a fair amount of
detail on how consensus was reached [40, 42, 46, 48, 49,
53, 54, 56], other guidelines provided minimal information
if not none at all [40, 41, 45, 47, 51, 55]. All authors
considered some health benefits, side effects, and/or risks
in formulating their recommendations, with the exception
of one [52]. Nearly all guidelines provided an explicit
link between their recommendations and the supporting
Table 1 Characteristics of eligible guidelines
Guideline Country (First Author) Developer CAM category Guideline topic
Fogarty 2015 [40] Australia Unclear Acupuncture Acupuncture for Anorexia Nervosa
Bryans 2014 [41] Canada Canadian Chiropractic Association Spinal manipulation Chiropractic Treatment for Neck Pain
Greenlee 2014 [42] United States Society for Integrative Oncology General CAM Integrative Therapies as Supportive
Care in Breast Cancer Patients
Yadav 2014 [43] United States American Academy of Neurology General CAM Complementary and Alternative
Medicine in Multiple Sclerosis
Deng 2013 [44] United States American College of Chest Physicians General CAM Complementary Therapies and
Integrative Medicine in Lung Cancer
Liu 2013 [45] China Unclear; Sponsored by World Health
Organization
Acupuncture Acupuncture for Herpes Zoster
Nahas 2013 [46] Canada Canadian Diabetes Association Herbals Natural Health Products for Diabetes
Holland 2012 [47] United States American Academy of Neurology General CAM NSAIDs and Complementary
Treatments for Episodic Migraine
Prevention
Bryans 2011 [48] Canada Canadian Chiropractic Association Spinal manipulation Chiropractic Treatment of Headache
Seffinger 2010 [49] United States American Osteopathic Association Spinal manipulation Osteopathic Manipulative Treatment
for Low Back Pain
Deng 2009 [50] United States Society for Integrative Oncology General CAM Complementary Therapies and
Botanicals for Integrative Oncology
Ravindran 2009 [51] Canada Canadian Psychiatric Association,
Canadian Network for Mood and
Anxiety Treatments
General CAM Complementary and Alternative
Medicine for the Management of
Major Depressive Disorder
Filshie 2006 [52] United Kingdom Unclear Acupuncture Providing Acupuncture for Cancer
Patients
Suchowersky 2006 [53] Canada American Academy of Neurology General CAM Neuroprotective Strategies and
Alternative Therapies for Parkinson
Disease
Anderson-Peacock 2005 [54] Canada Canadian Chiropractic Association,
Canadian Federation of Chiropractic
Regulatory Boards
Spinal manipulation Chiropractic Treatment for Neck Pain
Werneke 2005 [55] United Kingdom Unclear General CAM Complementary Therapies for Cancer
Mechanick 2003 [56] United States American Association of Clinical
Endocrinologists
Herbals Clinical Use of Dietary Supplements
and Nutraceuticals
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evidence with the exception of two guidelines in which
this was inconsistent [49, 52]. While some guidelines
explicitly stated that they were externally reviewed by
experts prior to publication [41, 46, 54, 56], many did
not [42–44, 47, 48, 52, 55]. Some guidelines failed to
mention the purpose and intent for, or the methods
employed for the external review [40, 45, 49–51, 53].
Most guidelines did not include a procedure for
updating the guideline [42, 44, 45, 47, 48, 50–56]
and, among those that did, one guideline provided a
detailed methodology [46].
Clarity of presentation
Generally, all guidelines offered specific and unambi-
guous recommendations. However, many typically lacked
one or more of the following details: identification of the
intent/purpose, relevant population, or caveats. All 17
guidelines scored highly in presenting different options for
the management of the condition or health issue, thus
contributing to this high scaled domain percentage
[40–56]. Key recommendations were also generally very
easily identifiable.
Applicability
One guideline discussed facilitators and barriers to
implementation of the recommendations [49]. Three
guidelines included advice and/or tools to support
implementation of the recommendations [49, 54, 56].
No guidelines addressed the resource implications of
implementing the recommendations. Two guidelines
provided monitoring and auditing criteria, while 14
guidelines contained little to no such information.
Editorial independence
Guidelines varied in reporting of the funding source or
competing interests of the members of the guideline
development panel. Several guidelines that declared a
funding source did not state whether funding source influ-
enced the content of the guideline [41, 42, 48, 53, 54, 56].
No guidelines explicitly stated that no funding sup-
ported their development. Guidelines also varied in
reporting of competing interests. Several guidelines
did not address competing interests [45, 51, 52, 55, 56].
While remaining guidelines did so, two did not spe-
cify how potential competing interests were identified
or considered, or how they may have influenced the
guideline development process or issuing of recom-
mendations [50, 53].
Discussion
To identify credible, knowledge-based resources upon
which patients and health care professionals can base
discussions and decisions about use of CAM, the pur-
pose of this research was to assess the quantity and
quality of CAM guidelines. This study identified 17
guidelines (nine specific CAM therapy, eight mixed CAM
therapies) published in 2003 or later that were relevant
to a variety of conditions and diseases. Quality as
assessed by the 23-item AGREE II instrument varied
widely across guidelines overall and by domain; two
guidelines scored 5.0 or higher in both average appraisal
score and average overall assessment [46, 49], and three
guidelines scored 3.5 or lower in both of these metrics
[45, 52, 55] (1 = strongly disagree; 7 = strongly agree that
criteria are met).
To our knowledge, no previous studies have assessed
the quantity and quality of guidelines on CAM therapies.
Thus, we believe that this is the first study to assess
the credibility and nature of CAM guidelines. The
findings are similar to those of guidelines on other
clinical topics. In this study of CAM guidelines, the
scaled domain percentages from highest to lowest were
clarity of presentation (85.3 %), scope and purpose
Table 2 Overall recommendations for use of appraised
guidelines
Guideline Appraiser 1 Appraiser 2
















Deng 2013 [44] No Yes with
Modifications
Liu 2013 [45] No Yes with
Modifications
Nahas 2013 [46] Yes with
Modifications
Yes












Deng 2009 [50] No Yes with
Modifications




Filshie 2006 [52] No No










Werneke 2005 [55] No No
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(83.3 %), rigour of development (61.2 %), editorial inde-
pendence (60.1 %), stakeholder involvement (52.0 %)
and applicability (20.7 %). In a previous study we found
that, among 137 guidelines on a wide variety of clinical
topics published from 2008 to 2013, the scaled domain
percentages were ordered in similar fashion from highest
(clarity of presentation 76.3 %) to lowest (applicability
43.6 %) [33]. Previous studies that examined a total of
654 guidelines published from 1980 to 2007 [57, 58], and
1,046 guidelines produced between 2005 and 2013 by
130 Australian guideline developers [59] also reported
similar findings. Therefore the variable and sub-optimal
quality of guidelines is not a unique phenomenon.
Notable strengths of this study included the use of a
comprehensive systematic review to identify eligible
CAM guidelines and the use of the validated AGREE II
instrument by which to assess their quality, which is the
internationally-accepted gold standard for appraising
guidelines [38]. The interpretation of these findings may
be limited by the fact that guidelines were independently
assessed by two appraisers instead of four as recom-
mended by the AGREE II instrument to optimize reli-
ability. To mitigate this and standardize scoring, ARG,
JYN and LL conducted an initial pilot-test during which
they independently appraised the same two guidelines,
then discussed the results and achieved consensus on
how to apply the AGREE II instrument. Following
appraisal of the 17 guidelines, ARG met with JYN and
LL to discuss and resolve any uncertainties without
unduly modifying legitimate discrepancies. This review
does not address all CAM therapies; three therapies
were chosen (herbal medicine, acupuncture, chiropractic
or osteopathic manipulation) because they were identi-
fied as having the largest evidence base, and were
therefore considered more likely to be the subject of
guidelines [39]. We may not have identified all guide-
lines that included these three types of CAM therapy
because, to establish a feasible scope, we did not search
for guidelines on specific clinical topics and then peruse
them for CAM-related content, and we did not search
all CAM journals or the Guidelines International Network
guideline library. We included CAM topics for which
there was likely to be available evidence such as guidelines.
Many patients use CAM lacking supporting evidence,
therefore, it may be useful to examine guidelines on a
broader range of CAM topics to evaluate the basis
for recommending those therapies.
By describing the quantity and quality of CAM
guidelines, this study revealed that few CAM guide-
lines are available to support informed and shared de-
cision-making among patients and health care
professionals. This likely reflects the lack of research on
CAM therapies. Others have identified numerous factors
that challenge CAM research including negative attitudes
about CAM therapies [60–65] and a lack of targeted
funding [66–69]. However, this is expected to change
given that CAM therapies continue to be used by more
than 40 % of the population in some regions of the world
Table 3 Scaled domain percentages for appraisers of each guideline











Fogarty 2015 [40] 94.4 47.2 65.6 75.0 94.4 47.2
Bryans 2014 [41] 88.9 47.2 75.0 80.6 88.9 47.2
Greenlee 2014 [42] 100.0 72.2 80.2 97.2 100.0 72.2
Yadav 2014 [43] 97.2 47.2 77.1 77.8 97.2 47.2
Deng 2013 [44] 83.3 58.3 60.4 91.7 83.3 58.3
Liu 2013 [45] 52.8 11.1 32.3 88.9 52.8 11.1
Nahas 2013 [46] 75.0 86.1 92.7 91.7 75.0 86.1
Holland 2012 [47] 88.9 30.6 57.3 86.1 88.9 30.6
Bryans 2011 [48] 69.4 41.7 74.0 80.6 69.4 41.7
Seffinger 2010 [49] 97.2 66.7 69.8 91.7 97.2 66.7
Deng 2009 [50] 58.3 69.4 51.0 97.2 58.3 69.4
Ravindran 2009 [51] 94.4 30.6 60.4 88.9 94.4 30.6
Filshie 2006 [52] 83.3 38.9 14.6 72.2 83.3 38.9
Suchowersky 2006 [53] 94.4 72.2 66.7 80.6 94.4 72.2
Anderson-Peacock 2005 [54] 97.2 47.2 77.1 77.8 97.2 47.2
Werneke 2005 [55] 69.4 50.0 27.1 69.4 69.4 50.0
Mechanick 2003 [56] 77.8 72.2 71.9 94.4 77.8 72.2
Ng et al. BMC Complementary and Alternative Medicine  (2016) 16:425 Page 7 of 10
[70, 71]; and patients continue to use CAM despite
documented risks associated with some CAM therapies
[22, 70–75]. As research emerges, so too will guidelines
that focus on CAM therapies [10].
This study also revealed that the quality of CAM
guidelines varied across domains within individual
guidelines, and across different guidelines. This finding
is relevant to those who will produce CAM guidelines in
the future, and to developers of existing CAM guidelines
that, when updated, could be improved. Apart from the
AGREE II instrument, numerous principles, frameworks,
criteria and checklists are available to help guideline
developers, including CAM guideline developers, to
generate the highest-quality products [76–81].
Conclusions
This study identified 17 guidelines published since
2003 on CAM therapies including herbal medicines,
acupuncture, and chiropractic or osteopathic manipula-
tion. Appraisal of these guidelines with the AGREE II
instrument revealed that quality varied within and across
guidelines. Some of these guidelines that achieved higher
AGREE II scores and favourable overall recommendations
could be used by patients and health care professionals
as the basis for discussion about the use of these CAM
therapies. In future updates, guidelines that achieved
variable or lower scaled domain percentage and overall
recommendations could be improved according to speci-
fications in the AGREE II instrument, and with insight
from a large number of resources that are available to
support guideline development and implementation
[75–80]. However, the fact that few CAM guidelines are
available to support informed and shared decision-making
between patients and health care professionals may con-
tinue to foster underuse of beneficial CAM therapies,
and overuse or contraindicated use of other CAM for
which there is no proven benefit or potential associated
risks. This finding justifies the need for greater research
on the safety and effectiveness of CAM therapies. Future
research should also identify CAM therapies other than
those reviewed here which are supported by sufficient
evidence to serve as the basis for guideline development.
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